Stereotactic Body Radiotherapy With or Without Selective Dismutase Mimetic for Pancreatic Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial
Lancet Oncol 2023 Dec 01;24(12)1387-1398, CM Taniguchi, JM Frakes, TA Aguilera, M Palta, B Czito, MS Bhutani, LE Colbert, J Abi Jaoude, V Bernard, S Pant, CD Tzeng, DW Kim, M Malafa, J Costello, G Mathew, N Rebueno, EJ Koay, P Das, EB Ludmir, MHG Katz, RA Wolff, S Beddar, GO Sawakuchi, S Moningi, RS Slack Tidwell, Y Yuan, PF Thall, RA Beardsley, J Holmlund, JM Herman, SE HoffeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.